Osaka Soda Co (4046) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
18 May, 2026Executive summary
Net sales rose 4.0% year-over-year to ¥24,114 million for the three months ended June 30, 2024, with operating profit up 17.9% to ¥3,309 million and profit attributable to owners of parent up 15.9% to ¥2,785 million.
Growth was driven by recovery in automobile production, increased demand for pharmaceutical purification materials, and resolution of prior manufacturing issues in basic chemicals.
The company continues to implement its medium-term management plan, focusing on strengthening existing businesses, new product development, and sustainability.
Financial highlights
Ordinary profit increased 16.0% year-over-year to ¥4,065 million.
Gross profit improved to ¥7,007 million from ¥6,237 million a year earlier.
Basic earnings per share rose to ¥109.78 from ¥94.50 year-over-year.
Comprehensive income declined 16.4% year-over-year to ¥3,799 million.
Outlook and guidance
Full-year net sales forecast is ¥103,000 million, up 8.9% year-over-year, with operating profit projected at ¥16,000 million (+52.5%) and profit attributable to owners of parent at ¥11,500 million (+50.3%).
No changes to previously announced forecasts; any future revisions will be disclosed as appropriate.
A 5-for-1 stock split is scheduled for October 1, 2024.
Latest events from Osaka Soda Co
- Operating profit jumped 41.7% on 7.6% higher sales, led by healthcare and functional chemicals.4046
Q2 202518 May 2026 - Profits surged on healthcare growth and supply recovery, with record highs forecast for FY2025 and FY2026.4046
Q4 202518 May 2026 - Profits surged on strong healthcare demand and supply recovery; full-year outlook maintained.4046
Q3 202518 May 2026 - Profits rose sharply despite lower sales, with upward guidance and enhanced shareholder returns.4046
Q2 202618 May 2026 - First-quarter profit rose 9.4% year-on-year, driven by healthcare and basic chemicals growth.4046
Q1 202618 May 2026 - Operating profit surged 21.6% and net profit rose 34.0% despite a 1.3% sales decline.4046
Q3 202618 May 2026 - Record profits and sales driven by Basic chemicals and Healthcare, with robust cash flow and new growth plans.4046
Q4 202618 May 2026